Scinai Net Income From Continuing Ops from 2010 to 2026
| SCNI Stock | USD 0.80 0.01 1.27% |
Net Income From Continuing Ops | First Reported 2010-12-31 | Previous Quarter 5.5 M | Current Value 5.8 M | Quarterly Volatility 53.6 M |
Check Scinai Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scinai Immunotherapeuti's main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 4.2 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 3.29, Dividend Yield of 0.0 or PTB Ratio of 0.23. Scinai financial statements analysis is a perfect complement when working with Scinai Immunotherapeuti Valuation or Volatility modules.
Scinai | Net Income From Continuing Ops | Build AI portfolio with Scinai Stock |
The Net Income From Continuing Ops trend for Scinai Immunotherapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Scinai Immunotherapeuti is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Scinai Immunotherapeuti's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Scinai Immunotherapeutics over the last few years. It is Scinai Immunotherapeuti's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scinai Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Scinai Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (66,440,993) | |
| Geometric Mean | 33,323,072 | |
| Coefficient Of Variation | (80.66) | |
| Mean Deviation | 50,297,655 | |
| Median | (109,194,000) | |
| Standard Deviation | 53,590,673 | |
| Sample Variance | 2872T | |
| Range | 115M | |
| R-Value | 0.87 | |
| Mean Square Error | 756.9T | |
| R-Squared | 0.75 | |
| Slope | 9,208,613 | |
| Total Sum of Squares | 45951.4T |
Scinai Net Income From Continuing Ops History
About Scinai Immunotherapeuti Financial Statements
Investors use fundamental indicators, such as Scinai Immunotherapeuti's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Scinai Immunotherapeuti's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 5.5 M | 5.8 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is there potential for Semiconductors & Semiconductor Equipment market expansion? Will Scinai introduce new products? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.872 | Earnings Share 4 | Quarterly Revenue Growth 0.361 | Return On Assets | Return On Equity |
Understanding Scinai Immunotherapeutics requires distinguishing between market price and book value, where the latter reflects Scinai's accounting equity. The concept of intrinsic value - what Scinai Immunotherapeuti's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Scinai Immunotherapeuti's price substantially above or below its fundamental value.
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Scinai Immunotherapeuti's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.